Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.1.1.67 (
thiopurine methyltransferase
)
551
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We explored the impact of mutations in the
NOTCH1
, FBW7 and PTEN genes on prognosis and downstream signaling in a well-defined cohort of 47 patients with pediatric T-cell acute lymphoblastic leukemia (T-ALL). In T-ALL lymphoblasts, we identified high-frequency mutations in
NOTCH1
(n=16), FBW7 (n=5) and PTEN (n=26).
NOTCH1
mutations resulted in 1.3- to 3.3-fold increased transactivation of an HES1 reporter construct over wild-type
NOTCH1
; mutant FBW7 resulted in further augmentation of reporter gene activity.
NOTCH1
and FBW7 mutations were accompanied by increased median transcripts for
NOTCH1
target genes (HES1, DELTEX1 and cMYC). However, none of these mutations were associated with treatment outcome. Elevated HES1, DELTEX1 and cMYC transcripts were associated with significant increases in transcript levels of several chemotherapy relevant genes, including MDR1, ABCC5, reduced folate carrier, asparagine synthetase,
thiopurine methyltransferase
, BCL2 and dihydrofolate reductase. PTEN transcripts positively correlated with HES1 and cMYC transcript levels. Our results suggest that (1) multiple factors should be considered with attempting to identify molecular-based prognostic factors for pediatric T-ALL, and (2) depending on the
NOTCH1
signaling status, modifications in the types or dosing of standard chemotherapy drugs for T-ALL, or combinations of agents capable of targeting
NOTCH1
, AKT and/or mTOR with standard chemotherapy agents may be warranted.
...
PMID:The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. 1934 1